SignatureFD’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-159
Closed -$20.4K 3394
2025
Q2
$20.4K Buy
159
+6
+4% +$623 ﹤0.01% 2048
2025
Q1
$13.5K Sell
153
-27
-15% -$2.63K ﹤0.01% 2246
2024
Q4
$15.7K Buy
180
+11
+7% +$1.01K ﹤0.01% 2179
2024
Q3
$15.6K Sell
169
-18
-10% -$1.79K ﹤0.01% 2161
2024
Q2
$20.2K Buy
187
+38
+26% +$3.8K ﹤0.01% 1968
2024
Q1
$14.1K Hold
149
﹤0.01% 2174
2023
Q4
$13.7K Sell
149
-136
-48% -$8.81K ﹤0.01% 2109
2023
Q3
$14.3K Sell
285
-7
-2% -$374 ﹤0.01% 2019
2023
Q2
$18.5K Buy
292
+123
+73% +$6.69K ﹤0.01% 1931
2023
Q1
$7.6K Buy
169
+52
+44% +$2.34K ﹤0.01% 2328
2022
Q4
$5.13K Sell
117
-85
-42% -$4.08K ﹤0.01% 2472
2022
Q3
$13K Sell
202
-61
-23% -$3.92K ﹤0.01% 1937
2022
Q2
$13K Buy
263
+124
+89% +$7.26K ﹤0.01% 1976
2022
Q1
$9K Buy
139
+32
+30% +$2.3K ﹤0.01% 2186
2021
Q4
$11K Buy
107
+17
+19% +$1.78K ﹤0.01% 2067
2021
Q3
$9K Buy
90
+2
+2% +$186 ﹤0.01% 2102
2021
Q2
$8K Buy
88
+1
+1% +$92 ﹤0.01% 2067
2021
Q1
$8K Buy
87
+1
+1% +$100 ﹤0.01% 1931
2020
Q4
$10K Hold
86
﹤0.01% 1687
2020
Q3
$8K Buy
86
+20
+30% +$1.54K ﹤0.01% 1704
2020
Q2
$5K Hold
66
﹤0.01% 1779
2020
Q1
$4K Buy
+66
New +$4.25K ﹤0.01% 1722

Other funds holding BPMC

SignatureFD's BPMC Position: Q3 2025 in Review

SignatureFD sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 159 shares — an estimated $20.4K sold.

SignatureFD first reported a position in BPMC in Q1 2020 and held it in 22 quarters. The position peaked at $20.4K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • SignatureFD reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • SignatureFD sold 159 Blueprint Medicines shares in Q3 2025, an estimated $20.4K.
  • SignatureFD first reported a position in Blueprint Medicines in Q1 2020 and held it in 22 quarters.
  • SignatureFD's Blueprint Medicines position peaked at $20.4K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on SignatureFD's 13F filing for Q3 2025, filed 21 Oct 2025.